Genpharmasec Limited has announced the approval of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors considered and approved these results, along with the limited review report, during their meeting held on August 11, 2026. The financial statements detail revenue and profit figures for the specified quarter and the corresponding periods.
Genpharmasec Approves Q1 FY27 Financial Results
The Board of Directors of Genpharmasec Limited convened on Tuesday, August 11, 2026, to review and approve the company’s unaudited standalone and consolidated financial results for the quarter that concluded on June 30, 2026. This approval was granted following a review by the Audit Committee.
Key Financial Highlights for Q1 FY27
The unaudited standalone financial results show a total income of ₹4,575.50 lakhs for the quarter ended June 30, 2026. Expenses for the same period amounted to ₹4,365.78 lakhs, resulting in a profit before tax of ₹209.72 lakhs. After accounting for a total tax expense of ₹52.76 lakhs, the profit for the period stood at ₹156.96 lakhs. The total comprehensive income for the period was ₹173.74 lakhs. Basic and diluted earnings per share were reported at ₹0.03 each.
Consolidated Financial Performance
On a consolidated basis, Genpharmasec Limited reported a total income of ₹5,008.34 lakhs for the quarter ended June 30, 2026. Total expenses were recorded at ₹4,982.57 lakhs, leading to a profit before tax of ₹25.77 lakhs. Following a tax expense of ₹43.13 lakhs, the consolidated profit for the period was (₹17.37 lakhs). Total comprehensive income for the period stood at (₹0.58 lakhs).
Board Meeting Details
The Board Meeting commenced at 03:00 p.m. and concluded at 03:50 p.m. on August 11, 2026. The company has filed these results in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial statements and limited review reports have been submitted for regulatory purposes.
Source: BSE
